Jill Winter
Chiron Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jill Winter.
Journal of Immunological Methods | 2001
Barbara Krebs; Robert Rauchenberger; Silke Reiffert; Christine Rothe; Michael Tesar; Elisabeth Thomassen; Manqiu Cao; Torsten Dreier; David Fischer; Adolf Höß; Landon Inge; Achim Knappik; Matthias Marget; Peter Pack; Xian-Qin Meng; Robert Schier; Peter Söhlemann; Jill Winter; Joachim Wölle; Titus Kretzschmar
The first version of the Human Combinatorial Antibody Library (HuCAL) is a single-chain Fv-based phage display library (HuCAL-scFv) with 2x10(9) members optimised for high-throughput generation and targeted engineering of human antibodies. 61% of the library genes code for functional scFv as judged by sequencing. We show here that since HuCAL-scFv antibodies are expressed in high levels in Escherichia coli, automated panning and screening in miniaturised settings (96- and 384-well format) have now become feasible. Additionally, the unique modular design of HuCAL-genes and -vectors allows the distinctly facilitated conversion of scFv into Fab, miniantibody and immunoglobulin formats, and the fusion with a variety of effector functions and tags not only convenient for therapeutic applications but also for high-throughput purification and detection. Thus, the HuCAL principle enables the rapid and high-throughput development of human antibodies by optimisation strategies proven useful in classical low molecular weight drug development. We demonstrate in this report that HuCAL is a very convenient source of human antibodies for various applications.
Nature Biotechnology | 1999
Marcus Ballinger; Venkatakrishna Shyamala; Louise D. Forrest; Maja Deuter-Reinhard; Laura V. Doyle; Jian-xin Wang; Lootsee Panganiban-Lustan; Jennifer R. Stratton; Gerald Apell; Jill Winter; Michael V. Doyle; Steven Rosenberg; W. Michael Kavanaugh
Fibroblast growth factors (FGFs) are being investigated in human clinical trials as treatments for angina, claudication, and stroke. We designed a molecule structurally unrelated to all FGFs, which potently mimicked basic FGF activity, by combining domains that (1) bind FGF receptors (2) bind heparin, and (3) mediate dimerization. A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) 1c extracellular domain but had no homology with FGFs. When fused with the c-jun leucine zipper domain, which binds heparin and forms homodimers, the polypeptide specifically reproduced the mitogenic and morphogenic activities of basic FGF with similar potency (EC50 = 240 pM). The polypeptide required interaction with heparin for activity, demonstrating the importance of heparin for FGFR activation even with designed ligands structurally unrelated to FGF. Our results demonstrate the feasibility of engineering potent artificial agonists for the receptor tyrosine kinases, and have important implications for the design of nonpeptidic ligands for FGF receptors. Furthermore, artificial FGFR agonists may be useful alternatives to FGF in the treatment of ischemic vascular disease.
Bioorganic & Medicinal Chemistry | 1999
Simon Ng; Bob Goodson; Anton F. Ehrhardt; Walter H. Moos; Mike Siani; Jill Winter
N-alkylated glycine trimers are generically referred to as peptoids. The identification of antimicrobial peptoids from a statistically unbiased diverse combinatorial chemistry library led to the design of the optimization peptoid library that we describe in this manuscript. This optimization library was designed using structural information from the most active peptoids in the unbiased library. Screening of the optimization library for antimicrobial activity identified a single pool of peptoids with activity against both Staphylococcus aureus and Escherichia coli. The active peptoids from this pool were active against drug sensitive and drug resistant organisms and represent novel antibacterial compounds.
Journal of Immunological Methods | 2001
Joseph Castillo; Bob Goodson; Jill Winter
M13 scFv display libraries are frontline research tools due to the rapidity in which target binding scFv can be obtained. Simple modifications of the standard affinity selection and amplification protocol allow for multiple targets to be panned simultaneously. Target peptide or protein production can become the rate-limiting step in a high throughput approach to antibody selection. To overcome this obstacle and to save both time and money, we have displayed the target peptides on T7 phage particles. In this paper we demonstrate that these particles can be used directly to select peptide specific scFv. We have discovered that the selection is most efficient when a linker separates the display from the T7 coat protein and when a continuous subtraction is employed. We have used antibodies selected in this fashion to characterize target proteins in cell lysates, immuno-precipitations and immuno-histochemistry.
Blood | 1999
Vivien W. Chan; Srinivas Kothakota; Michael Rohan; Lootsee Panganiban-Lustan; Jason P. Gardner; Matthew Wachowicz; Jill Winter; Lewis T. Williams
Antimicrobial Agents and Chemotherapy | 1999
Bob Goodson; Anton F. Ehrhardt; Simon Ng; John M. Nuss; Kirk W. Johnson; Marty Giedlin; Ralph Yamamoto; Walter H. Moos; Anke Krebber; Martha Ladner; Mary Beth Giacona; Charles R. Vitt; Jill Winter
Archive | 2002
Christoph Reinhard; Julie Klinger; Anne B. Jefferson; Jaime Escobedo; Fillipo Randazzo; Jill Winter; Robert Goodson; Weimin Qi
Drug Development Research | 1994
Jill Winter
Archive | 2001
Christoph Reinhard; Anne B. Jefferson; Douglas R. Den-Otter; Jill Winter
Archive | 1999
Keting Chu; Hong Xin; Vivien W. Chan; Srinivas Kothakota; Lewis T. Williams; Jill Winter